Eversept Partners is a New York-based hedge fund that focuses on investing in companies from the healthcare sector. It was founded by its current portfolio manager Mr. Kamran Moghtaderi, who previously worked as an Analyst and Portfolio Manager at Apis Capital Advisors, LLC. Mr. Moghtaderi’s investment experience is much more extensive than this, as prior to joining Apis Capital Advisors ,LLC he was a Global Research Analyst at J&W Seligman & Company where he managed life sciences sectors (from pharmaceuticals to devices and healthcare services), and prior to J&W Seligman & Company he worked at Gambro Group. Mr. Moghtaderi holds a Masters in Business Administration from Harvard University, and a Bachelor of Science in Biology from the University of Los Angeles.
The fund is an advisor of Eversept Global Health Care Fund, L.P, a long/short global healthcare equity fund, which was launched by Mr. Moghtaderi in 2011. The fund’s investment philosophy turned out to be very efficient, as it had some very good years in terms of returns. Eversept Global Healthcare Fund, L.P. delivered a return of fantastic 38.31% in 2013, 43.43% in 2014, 11.30% in 2015, 43.39% in 2016, 2.24% in 2017, and 9.11% in 2018 (since January until October 29). Its total return amounted to 233.49%, compound annual return was of 17.42%, and its worst drawdown was 12.14. As reported in the fund’s Form ADV from July 26, 2018, it has around 370,79 million in regulatory assets under management.
Insider Monkey’s flagship strategy identifies the best performing 100 hedge funds at the end of each quarter and invests in their consensus stock picks. This way it is always invested in the best ideas of the best performing hedge funds and is able to generate much higher returns than the market. Since its inception in May 2014, our flagship strategy generated a cumulative return of 96.9%, beating the S&P 500 ETF (SPY) by over 40 percentage points (see the details here).
At the end of the third quarter, Eversept Partners’ portfolio was valued around $207.75 million, after the fund has added 20 new positions and dumped around 22 companies. The biggest position the fund held on September 30 was in Zogenix, Inc. (NASDAQ:ZGNX), and it included 419,279 shares, with a value of $20.8 million. The fund doesn’t look for the companies that are being widely popular, hence it hasn’t invested in any of the 30 most popular stocks among hedge funds in Q3 of 2018. More details about the fund’s third quarter portfolio changes you can find on the next page.
The second largest holding the fund disclosed at the end of the third quarter was in R1 RCM Inc (NASDAQ:RCM), and after the fund has lowered its stake by 7% it counted 1.69 million shares valued $17.12 million. This is a healthcare revenue cycle management company that provides services to hospitals and various other healthcare institutions. Over the past 12 months, the company’s stock gained 81.8%, and at the moment of writing, it is trading at $8.09.
Among the biggest new additions to Eversept Partners’ portfolio were Merck & Co., Inc. (NYSE:MRK), Danaher Corporation (NYSE:DHR), and Xenon Pharmaceuticals Inc (NASDAQ:XENE). In Merck & Co, it has initiated a position that was valued $10.56 million, counting 147,800 shares, while in Danaher Corporation it has built a stake worth $3.87 million, which included 35,604 outstanding shares. It Xenon Pharmaceuticals it has established a valuable position of $2.77 million, by obtaining 209,739 shares. While Merck & Co are both pharmaceutical companies, Danaher Corporation is a more diversified company that produces a variety of professional medical, commercial and industrial products. Year to date, Danaher’s stock gained 7.97%, and it is currently trading at $99.81.
Among the biggest sold out positions in the third quarter were those in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). In BioMarin Pharmaceutical, Everspet Partner sold out a stake that was valued at the end of the second quarter at $7.94 million, on the account of 84,257 shares. And, in Alnylam Pharmaceuticals the fund dropped its position which was worth around $6.25 million and counted 63,493 shares.
Eversept Partners 是一家总部位于纽约的对冲基金，专注于投资医疗行业的公司。该公司由其现任投资组合经理 Kamran Moghtaderi 先生创立，他曾在 Apis Capital Advisors , LLC 担任分析师和投资组合经理。Moghtaderi 先生的投资经验比这要广泛得多，在加入 Apis Capital Advisors , LLC 之前，他曾在 J & W Seligman & Company 担任全球研究分析师，管理生命科学领域（从制药到设备和医疗服务），在 J & W Seligman & Company 之前，他曾在 Gambro Group 工作。Moghtaderi 先生拥有哈佛大学工商管理硕士学位和洛杉矶大学生物学学士学位。
该基金是 Eversept Global Health Care Fund , L .P .是一家长期/短期的全球医疗保健股票基金，由 Moghtaderi 于2011年发起。事实证明，该基金的投资理念非常有效，因为它在回报方面有一些非常好的年份。Eversept Global Healthcare Fund , L.P .2013年的回报率高达38.31%，2014年为43.43%，2015年为11.30%，2016年为43.39%，2017年为2.24%，2018年为9.11%（自1月至10月29日）。总回报233.49%，年复合回报率17.42%，最差跌幅12.14%。如2018年7月26日基金表 ADV 所报告，其管理的监管资产约为37,079万元。
InsiderMonkey 的旗舰战略确定了每个季度末表现最佳的100只对冲基金，并投资于他们普遍认同的选股。这样，它总是投资于表现最好的对冲基金的最佳想法，并能够产生比市场高得多的回报。自2014年5月成立以来，我们的旗舰战略累计产生了96.9%的回报，比标准普尔500指数 ETF （ SPY ）高出40个百分点以上（详见此处）。
截至第三季度末， Eversept Partners 的投资组合价值约为2.0775亿美元，此前该基金新增了20个头寸，并抛售了大约22家公司。该基金在9月30日持有的最大头寸是 Zogenix , Inc .（纳斯达克代码： ZGNX ），其中包括419,279股，价值2,080万美元。该基金不寻找广受欢迎的公司，因此在2018年第三季度，它没有投资对冲基金中最受欢迎的30只股票中的任何一只。有关该基金第三季度投资组合变化的更多详细信息，您可以在下一页找到。
截至第三季度末，该基金披露的第二大持股人是 R1 RCM Inc （纳斯达克代码： RCM ），在该基金将其持股比例降低7%后，该基金计入了价值1712万美元的169万股股票。这是一家医疗收入周期管理公司，为医院和其他各种医疗机构提供服务。在过去12个月里，该公司股价上涨了81.8%，而在撰写本报告时，该公司股价为8.09美元。
Eversept Partners 投资组合中最大的新成员包括 Merck & Co ., Inc .（ NYSE ： MRK ）、 Danaher Corporation （ NYSE ： DHR ）和 XenPharmaceuticals Inc （ NASDAQ ： XENE ）。在默克公司( Merck & Co )中，该公司已启动了一个价值1056万美元的头寸，计14.78万股，而在丹纳赫公司( Danaher Corporation )中，该公司已建立了价值387万美元的股份，其中包括35604股流通股。其 Xeon Pharmaceuticals 通过取得209,739股，已建立价值277万美元的仓位。虽然默克公司都是制药公司，但丹纳赫公司是一个更加多元化的公司，生产各种专业的医疗，商业和工业产品。今年迄今，丹纳赫公司股价上涨7.97%，目前股价为99.81美元。
第三季度卖出最多的头寸是 BioMarin 制药公司（ NASDAQ ： BMRN ）和 Alnyam 制药公司（ NASDAQ ： ALNY ）。在 BioMarin Pharmaceutical ， Everspet Partner 以84,257股的价格出售了第二季度末估值为794万美元的股份。此外，在 Alnyam Pharmaceuticals ，该基金放弃了价值约625万美元的头寸，计算出63,493股。